RU2417792C2 - Иммуномодуляторные стероиды - Google Patents

Иммуномодуляторные стероиды Download PDF

Info

Publication number
RU2417792C2
RU2417792C2 RU2006133273/04A RU2006133273A RU2417792C2 RU 2417792 C2 RU2417792 C2 RU 2417792C2 RU 2006133273/04 A RU2006133273/04 A RU 2006133273/04A RU 2006133273 A RU2006133273 A RU 2006133273A RU 2417792 C2 RU2417792 C2 RU 2417792C2
Authority
RU
Russia
Prior art keywords
use according
ester
oac
inflammation
immunomodulatory
Prior art date
Application number
RU2006133273/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006133273A (ru
Inventor
Кларенс Натаниэл АЛЕМ (US)
Кларенс Натаниэл АЛЕМ
Джеймс Мартин ФРИНКЕ (US)
Джеймс Мартин ФРИНКЕ
КАРВАЛЬО Луис Даниэль дос Анхос ДЕ (PT)
КАРВАЛЬО Луис Даниэль Дос Анхос ДЕ
Вильям ХЭГГИ (PT)
Вильям ХЭГГИ
Патрик Т. ПРЕНДЕРГАСТ (IE)
Патрик Т. ПРЕНДЕРГАСТ
Кристофер Л. РИДИНГ (US)
Кристофер Л. Ридинг
Крупакар Пол ТАДИКОНДА (US)
Крупакар Пол ТАДИКОНДА
Рассэль Нэйл ВЕРНОН (US)
Рассэль Нэйл ВЕРНОН
Original Assignee
Харбор Биосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Харбор Биосайенсиз, Инк. filed Critical Харбор Биосайенсиз, Инк.
Publication of RU2006133273A publication Critical patent/RU2006133273A/ru
Application granted granted Critical
Publication of RU2417792C2 publication Critical patent/RU2417792C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2006133273/04A 1999-03-23 2000-03-23 Иммуномодуляторные стероиды RU2417792C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-03-23
US14002899P 1999-06-16 1999-06-16
US60/140,028 1999-06-16
US41490599A 1999-10-08 1999-10-08
US09/414,905 1999-10-08
US16404899P 1999-11-08 1999-11-08
US60/164,048 1999-11-08
PCT/US2000/007883 WO2000056757A1 (en) 1999-03-23 2000-03-23 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2001128881/04A Division RU2295534C2 (ru) 1999-03-23 2000-03-23 Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений

Publications (2)

Publication Number Publication Date
RU2006133273A RU2006133273A (ru) 2008-03-27
RU2417792C2 true RU2417792C2 (ru) 2011-05-10

Family

ID=27494614

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2006133273/04A RU2417792C2 (ru) 1999-03-23 2000-03-23 Иммуномодуляторные стероиды
RU2001128881/04A RU2295534C2 (ru) 1999-03-23 2000-03-23 Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2001128881/04A RU2295534C2 (ru) 1999-03-23 2000-03-23 Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений

Country Status (22)

Country Link
EP (1) EP1163256B1 (enExample)
JP (1) JP2002540119A (enExample)
KR (2) KR20070007394A (enExample)
CN (1) CN1243767C (enExample)
AP (1) AP2001002285A0 (enExample)
AT (1) ATE259825T1 (enExample)
AU (1) AU781997B2 (enExample)
BR (1) BR0009476A (enExample)
CA (1) CA2365081A1 (enExample)
CZ (1) CZ20013420A3 (enExample)
DE (1) DE60008353T2 (enExample)
DK (1) DK1163256T3 (enExample)
ES (1) ES2215631T3 (enExample)
HK (1) HK1046002B (enExample)
HU (1) HUP0203429A3 (enExample)
IL (1) IL144916A0 (enExample)
NO (2) NO320801B1 (enExample)
NZ (1) NZ513803A (enExample)
OA (1) OA11850A (enExample)
PT (1) PT1163256E (enExample)
RU (2) RU2417792C2 (enExample)
WO (1) WO2000056757A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1228083A2 (en) 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
EP1372664A1 (en) 2001-03-01 2004-01-02 Hollis-Eden Pharmaceuticals Inc. Use of certain steroids for treatment of blood cell deficiencies
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
RU2356555C2 (ru) * 2003-12-26 2009-05-27 Ниссан Кемикал Индастриз, ЛТД Антинейтрофильное средство
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN106565654B (zh) * 2016-10-14 2018-08-31 云南中烟工业有限责任公司 一种从白云参中提取的新型黄酮类化合物、其制备方法及其用途
BR112020021278A2 (pt) * 2018-06-01 2021-01-26 Société des Produits Nestlé S.A. butirato dietário
US10836788B2 (en) 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
AU2020398693A1 (en) * 2019-12-05 2022-04-28 Société des Produits Nestlé S.A. Dietary butyrate
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH197784A (de) * 1934-05-25 1938-05-15 Schering Kahlbaum Ag Verfahren zu Darstellung von D5,6-trans-Androstendiol-3,17.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8706717A1 (es) * 1983-08-02 1987-07-01 Research Corp Metodo de preparar esteroides
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
JPH0289327A (ja) * 1988-09-27 1990-03-29 Matsushita Electron Corp 銀ペースト塗布装置
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH197784A (de) * 1934-05-25 1938-05-15 Schering Kahlbaum Ag Verfahren zu Darstellung von D5,6-trans-Androstendiol-3,17.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response

Also Published As

Publication number Publication date
NZ513803A (en) 2004-06-25
EP1163256A1 (en) 2001-12-19
HUP0203429A2 (hu) 2003-01-28
CN1243767C (zh) 2006-03-01
KR100717897B1 (ko) 2007-05-14
HK1046002B (zh) 2006-10-20
DE60008353T2 (de) 2005-09-08
NO20014588D0 (no) 2001-09-21
ATE259825T1 (de) 2004-03-15
JP2002540119A (ja) 2002-11-26
HUP0203429A3 (en) 2004-07-28
CN1355809A (zh) 2002-06-26
RU2001128881A (ru) 2003-09-27
CA2365081A1 (en) 2000-09-28
NO20056167L (no) 2001-11-21
RU2295534C2 (ru) 2007-03-20
DE60008353D1 (de) 2004-03-25
HK1046002A1 (en) 2002-12-20
KR20020003217A (ko) 2002-01-10
AP2001002285A0 (en) 2001-12-31
DK1163256T3 (da) 2004-06-28
WO2000056757A1 (en) 2000-09-28
EP1163256B1 (en) 2004-02-18
IL144916A0 (en) 2002-06-30
BR0009476A (pt) 2002-02-19
AU3919000A (en) 2000-10-09
KR20070007394A (ko) 2007-01-15
CZ20013420A3 (cs) 2002-04-17
AU781997B2 (en) 2005-06-23
NO320801B1 (no) 2006-01-30
PT1163256E (pt) 2004-07-30
ES2215631T3 (es) 2004-10-16
NO20014588L (no) 2001-11-21
RU2006133273A (ru) 2008-03-27
OA11850A (en) 2006-03-06

Similar Documents

Publication Publication Date Title
RU2417792C2 (ru) Иммуномодуляторные стероиды
RU2210574C2 (ru) Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
RU96115774A (ru) Производные 11-(замещенный фенил)-эстра-4,9-диена
RU98115774A (ru) Новые производные 19-нор-прегнена
EE03525B1 (et) Kompositsioonid nuumrakkude vahendatud põletikuliste seisundite raviks
TW240215B (enExample)
EP1526132A3 (de) Substituierte Oxazolidinone und ihre Verwendung im Gebiet der Blutgerinnung
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
CA2182771A1 (en) 11-(substituted phenyl)-estra-4,9-diene derivatives
DE69917459D1 (de) Phenoxyessigsäure-verbindungen und medizinische zusammensetzungen, die diese enthalten
KR940014293A (ko) 아이오드화 아로일옥시 에스테르
RU98122210A (ru) Производные андростена
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
KR970074765A (ko) 비타민 d₃ 동족체
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
KR950032267A (ko) 11,21-비스페닐-19-노르프레그난 유도체
KR960014152A (ko) 17-스피로메틸렌 락톤 또는 락톨 그룹을 갖는 스테로이드
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
JP2002540119A5 (enExample)
RU95118123A (ru) Стероиды с 17-спирометилен-лактоновой или -лактольной группой
RU2002117440A (ru) Новые андрогены
KR930700502A (ko) 6-아미노옥타히드로인돌리진트리올 유도체
JPH1036365A5 (enExample)
RU2002108723A (ru) Неароматические эстрогенные стероиды с углеводородным заместителем в положении 11
JP2003521457A5 (enExample)

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20101119

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20101119

MM4A The patent is invalid due to non-payment of fees

Effective date: 20140324